Literature DB >> 23904001

Vascular endothelial growth factor ‑634G/C polymorphism is associated with increased breast cancer risk and aggressiveness.

Doonyapat Sa-Nguanraksa1, Tuenjai Chuangsuwanich, Tawatchai Pongpruttipan, Tanawan Kummalue, Supakorn Rojananin, Adune Ratanawichhitrasin, Poramaporn Prasarttong-Osoth, Suebwong Chuthatisith, Pongthep Pisarnturakit, Waraporn Aeumrithaicharoenchok, Pradit Rushatamukayanunt, Visnu Lohsiriwat, Mongkol Boonsripitayanon, Prida Malasit, Pornchai O-Charoenrat.   

Abstract

Polymorphisms in the promoter and 5' untranslated region of vascular endothelial growth factor (VEGF) have been associated with VEGF levels. To investigate the role of VEGF polymorphisms in breast cancer, the VEGF ‑2578C/A, ‑1498C/T, ‑1154G/A and ‑634G/C polymorphisms were genotyped in 483 breast cancer patients and 524 healthy controls. VEGF mRNA levels in breast cancer tissue were determined using semi‑quantitative RT‑PCR. The genotypes, ‑634G/C and ‑634C/C, were associated with an increased risk for breast cancer when compared with the ‑634G/G genotype. The VEGF ‑634G/C genotype was associated with tumor size >20 mm, perineural invasion and stage II‑IV. Individuals with ‑634C/C had lower disease‑free survival. Patients with the VEGF ‑634C/C genotype exhibited the highest VEGF mRNA levels. High VEGF mRNA expression correlated with tumor size >20 mm, presence of lymphovascular invasion and axillary nodal metastasis. These observations suggested that VEGF ‑634G/C polymorphisms have a significant role in breast cancer susceptibility and aggressiveness.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23904001     DOI: 10.3892/mmr.2013.1607

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  13 in total

1.  Association between VEGF -634G/C polymorphism and osteonecrosis of the femoral head susceptibility: a meta analysis.

Authors:  Yaosheng Liu; Zhicheng Zhang; Shubin Liu; Xiuyun Su; Shiguo Zhou
Journal:  Int J Clin Exp Med       Date:  2015-07-15

2.  Role of five small nucleotide polymorphisms in the VEGF gene on the susceptibility to osteosarcoma and overall survival of patients.

Authors:  Jian-Qiang Liu; Xia Bai; DE-Chen Duan; Ai-Xia Dou
Journal:  Oncol Lett       Date:  2015-06-19       Impact factor: 2.967

3.  Predictive value of vascular endothelial growth factor polymorphisms on the risk of renal cell carcinomas: a case-control study.

Authors:  Guangjian Lu; Yuqian Dong; Qunmei Zhang; Luyang Jiao; Shujuan Yang; Beili Shen
Journal:  Tumour Biol       Date:  2015-06-05

4.  Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib.

Authors:  Vincenzo Marotta; Concetta Sciammarella; Mario Capasso; Alessandro Testori; Claudia Pivonello; Maria Grazia Chiofalo; Rosario Pivonello; Luciano Pezzullo; Gerardo Botti; Annamaria Colao; Antongiulio Faggiano
Journal:  Endocrine       Date:  2016-12-16       Impact factor: 3.633

5.  Association of vascular endothelial growth factor polymorphisms with clinical outcome of renal cell carcinoma patients.

Authors:  Weifeng Zhong; Xiaohong Wang; Bin Pan; Zexuan Su
Journal:  Tumour Biol       Date:  2014-07-03

6.  Prognostic evaluation of VEGFA genotypes and haplotypes in a cohort of Brazilian women with non metastatic breast cancer.

Authors:  Hayra de Andrade Vieira-Monteiro; Daniely Regina Freitas-Alves; Marcelo Sobral-Leite; João Marcos de Azevedo Delou; Sheyla Maria Torres Goulart-Citrangulo; Camila Telles do Nascimento; Thales Nascimento E Castro; Sérgio Koifman; Jamila Alessandra Perini; Rosane Vianna-Jorge
Journal:  Cancer Biol Ther       Date:  2016-06-02       Impact factor: 4.742

7.  Vascular endothelial growth factor (VEGF) gene polymorphisms and breast cancer risk in Punjabi population from North West India.

Authors:  Ruhi Kapahi; Kamlesh Guleria; Vasudha Sambyal; Mridu Manjari; Meena Sudan; Manjit Singh Uppal; Neeti Rajan Singh
Journal:  Tumour Biol       Date:  2014-08-09

8.  Survival outcome of combined GnRH agonist and tamoxifen is comparable to that of sequential adriamycin and cyclophosphamide chemotherapy plus tamoxifen in premenopausal patients with early breast cancer.

Authors:  Doonyapat Sa-Nguanraksa; Thitikon Krisorakun; Wanee Pongthong; Pornchai O-Charoenrat
Journal:  Mol Clin Oncol       Date:  2019-08-20

9.  Association of VEGF haplotypes with breast cancer risk in North-West Indians.

Authors:  Vasudha Sambyal; Kamlesh Guleria; Ruhi Kapahi; Mridu Manjari; Meena Sudan; Manjit Singh Uppal; Neeti Rajan Singh
Journal:  BMC Med Genomics       Date:  2021-08-24       Impact factor: 3.063

10.  Predictive value of vascular endothelial growth factor polymorphisms on the clinical outcome of renal cell carcinoma patients.

Authors:  Nan Ma; Li-Wei Li; Jing-Liang Cheng
Journal:  Oncol Lett       Date:  2014-12-12       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.